AstraZeneca (AZN, Financial) and Amgen (AMGN) have jointly submitted a marketing application for the TSLP monoclonal antibody, Tezepelumab, as an injectable treatment. This submission is likely aimed at addressing asthma, based on the drug's clinical development progress. In China, Tezepelumab has completed a Phase III clinical trial for asthma treatment, administered via subcutaneous injection every four weeks.
TSLP is released in response to various triggers associated with diseases like asthma, chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease, and eosinophilic esophagitis. Increased TSLP expression is linked to disease severity. Blocking TSLP may prevent immune cells from releasing pro-inflammatory cytokines, potentially preventing disease progression and improving disease management.
Research indicates that targeting TSLP released by airway epithelium could be a promising future approach for treating lower respiratory tract diseases. Studies suggest that for patients with severe, uncontrolled asthma, Tezepelumab treatment can significantly increase the likelihood of achieving complete clinical response and remission compared to a placebo.
